Madrigal Pharmaceuticals, Inc.
Financials
Valuation Metrics
Madrigal Pharmaceuticals, Inc.'s Market Cap is $12.32B. At end of 2025 it was $13.06B. Ranked #808 of 3,121 in US market (top 26%), #254 of 1,463 on NASDAQ (top 17%), #40 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $12.32B | US#808/3,121 Sec#40/266 |
| Revenue | $1.28B | US#1,738/3,121 Sec#45/266 |
| Net Income | $-325M | US—/3,121 Sec—/266 |
| Total Assets | $1.24B | US#2,370/3,121 Sec#81/266 |
| Net Assets | $524M | US#2,209/3,121 Sec#106/266 |
| Employees | 915 | US#2,023/3,121 Sec#56/266 |
| Value | ||
| P/B | 23.53x | US#2,819/3,121 Sec#223/266 |
| P/S | 9.60x | US#2,674/3,121 Sec#111/266 |
| FCF Yield | -1.67% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -62.07% | US#2,726/3,121 Sec#176/266 |
| ROA | -26.12% | US#2,861/3,121 Sec#147/266 |
| Op. Margin | -25.13% | US#2,625/3,121 Sec#103/266 |
| Revenue Growth | 149.04% | US#68/3,121 Sec#25/266 |
| Financial Health | ||
| Debt Ratio | 137.65% | US#1,410/3,121 Sec#183/266 |
| Total Debt | $348M | US#2,053/3,121 Sec#74/266 |
| FCF | $-206M | US#2,780/3,121 Sec#208/266 |
| Cash | $293M | US#1,437/3,121 Sec#80/266 |
| Current Ratio | 3.20x | US#732/3,121 Sec#183/266 |
| Performance | ||
| 1Y Return | 28.02% | US#958/3,121 Sec#141/266 |
| 1M Return | 1.91% | US#724/3,121 Sec#75/266 |
| From 52W High | -13.11% | US#977/3,121 Sec#66/266 |
| 1Y MDD | -29.36% | US#1,365/3,121 Sec#86/266 |
| Trading | ||
| Volume | 151,696 shares | US#2,780/3,121 Sec#257/266 |
| Trading Value | $81M | US#960/3,121 Sec#66/266 |
| Per Share | ||
| EPS | $-14.10 | US—/3,121 Sec—/266 |
| BPS | $22.72 | US#1,127/3,121 Sec#23/266 |
Company Info
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.